OneThree Biotech
OneThree Biotech uses biology-driven artificial intelligence to improve how companies discover and prioritize therapeutic candidates. It combines machine learning and interpretable models with more than 30 types of chemical, biological, and clinical data (including multi-omics and assay readouts) to predict potential therapeutics and their mechanisms of action. The platform supports target discovery, compound and combination therapy identification, toxicity prediction, and biomarker selection. OneThree operates as a B2B AI-driven drug discovery platform working with biotech and pharmaceutical partners and has validated predictions in collaboration with major industry players.
OneThree Biotech
OneThree Biotech uses biology-driven artificial intelligence to improve how companies discover and prioritize therapeutic candidates. It combines machine learning and interpretable models with more than 30 types of chemical, biological, and clinical data (including multi-omics and assay readouts) to predict potential therapeutics and their mechanisms of action. The platform supports target discovery, compound and combination therapy identification, toxicity prediction, and biomarker selection. OneThree operates as a B2B AI-driven drug discovery platform working with biotech and pharmaceutical partners and has validated predictions in collaboration with major industry players.
TL;DR
What they do: Biology-driven AI platform for preclinical drug discovery (target, compound/combination ID, toxicity, biomarkers)
Founded / HQ: 2018; New York City
Business model: B2B partnerships with biotech and pharmaceutical companies
Seed funding: $2.5M seed (Mar 2020) led by Primary Venture Partners and Meridian Street Capital
Company Overview
Problem Domain
Preclinical drug discovery and candidate prioritization
Founded
2018
Industry
Biotechnology
Tech Stack
Funding Track Record
$2,500,000
Seed round announced to support platform and infrastructure development